Oruka Therapeutics, Inc.

Contributing Author

Recent Articles by Oruka Therapeutics, Inc.

Feb-09	Oruka Therapeutics to Participate in Multiple Upcoming Conferences ORKA GlobeNewswire
Jan-12	Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 ORKA +10.16% GlobeNewswire
Jan-06	Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference ORKA GlobeNewswire
Dec-11	Oruka Therapeutics Announces New Board Member and Board Transition ORKA GlobeNewswire
Nov-12	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update ORKA -6.78% ORKA GlobeNewswire
Oct-29	Oruka Therapeutics to Present at Multiple November Investor Conferences ORKA GlobeNewswire
Sep-17	Oruka Therapeutics Announces $180 Million Private Placement ORKA +8.79% GlobeNewswire
Sep-17	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 ORKA +8.79% GlobeNewswire
Aug-11	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update ORKA +6.90% ORKA GlobeNewswire
Jul-21	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September ORKA -5.30% GlobeNewswire
Jul-01	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer ORKA +6.86% ORKA +5.26% GlobeNewswire
May-21	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference ORKA GlobeNewswire
May-20	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody ORKA GlobeNewswire
May-14	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update ORKA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.